临床药师参与非小细胞肺腺癌口服厄洛替尼致皮疹的药学监护  

Pharmaceutical Care for Non-small Cell Lung Cancer Patients with Skin Rash Induced by Oral Erlotinib by Clinical Pharmacists

作　　者：李晓兰[1] 

机构地区：[1]焦作市第二人民医院药学部,河南焦作454001

出　　处：《中国医院用药评价与分析》2016年第5期697-699,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:了解靶向抗肿瘤药厄洛替尼在药物治疗过程中引发药品不良反应(adverse drug reaction,ADR)的特点及规律。方法:介绍临床药师参与非小细胞肺腺癌患者口服厄洛替尼致皮疹患者的病例,分析抗肿瘤药治疗方案、ADR监测及处理,评估抗肿瘤药使用后皮疹的发生情况。结果与结论:临床药师通过运用所学的药学知识,结合抗肿瘤药的药动学特点,参与厄洛替尼致皮疹的药物治疗,为临床医师提供合理的用药方案,为患者讲解药学知识、用药注意事项及ADR的防范措施,与医护人员协作,能发挥专业特长,更好地为患者服务。OBJECTIVE： To investigate the regulations and characteristics of adverse drug reactions（ ADRs） induced by targeted anti-tumor drugs erlotinib. METHODS： The clinical pharmacists participated in the treatment of non-small cell lung cancer patients with skin rash induced by oral erlotinib,analyzed the therapeutic regimen of anti-tumor drugs,monitoring and control of ADRs,and evaluated the incidence of skin rash induced by anti-tumor drugs after administration. RESULTS CONCLUSIONS： Through the pharmaceutical knowledge combined with pharmacokinetics of anti-tumor drugs,the clinical pharmacists participated in the therapeutic regimen of skin rash induced by oral erlotinib,assisted the clinicians to formulate rational therapeutic regimen,and communicated with the patients about the pharmaceutical knowledge,attention of rational drug use and provision of ADRs. Meanwhile,when together with the medical staffs,the clinical pharmacists can give full play to the professional expertise,and provide better service for the patients.

关 键 词：临床药师 厄洛替尼 皮疹 药学监护 

分 类 号：R969.3[医药卫生—药理学]